Gilead Sciences, Inc.

Gilead Pharmasset LLC

Gilead Calistoga LLC

Global Blood Therapeutics, Inc.

Sierra Oncology, Inc.

Glaxosmithkline LLC

Fang Wang

Stephan D Parent

Patricia Andres

Bing Shi

Ernest A Carra

Dimitrios Stefanidis

Jerry B Evarts

Paul A Roethle

Duong D Tran

Olga Viktorovna Lapina

Jeffrey N Hemenway

Matthew Robert Warr

James Andrew Whitney

Yan Xin

Scott Alan Wolckenhauer

Henry G Morrison

Michael J Gerber

Robert William Scott

Keiko Sujino

Brandon Heath Brown

Erik Mogalian

Brandon H Brown

Troy Reynolds

Travis Lee Houston

Richard Hung Chiu Yu

Suzanne Buttar

Tracy Ehiwe

Troy Evan Reynolds

Zhuoyi Su

Courtney S Johnson

Dazhan Liu

Christopher Worrall

Vahid Zia

Henry Morrison

Melissa Jean Casteel

Krista Marie Diaz

Zhi Xian Wang

Jacqueline Ching-See Woo

Kathleen Dashner

Hyuk-Jun Jung

Mun Sik Seo

Yoo Joong Kim

Paul Bernard Hurley

Valeriya Smolenskaya

Duong Tran

Forms of (S)-2-hydroxy-6-((4-(2-(2-hydroxyethyl)nicotinoyl)morpholin-3-yl)methoxy)benzaldehyde (Compound I), or salts or solvates thereof, were prepared and characterized in the solid state. Also provided are processes of manufacture and methods of using the forms of Compound I.

Solid forms of a modulator of hemoglobin

The present invention relates to stable novel salt forms of N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide that are suitable for the preparation of pharmaceutical formulations thereof, and their therapeutic use.

(N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide

N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide

Crystalline solid forms of methyl {(2S)-1-[(2S,5S)-2-(9-{2-[(2S,4S)-1-{(2R)-2-[(methoxycarbonyl)amino]-2-phenylacetyl}-4-(methoxymethyl)pyrrolidin-2-yl]-1H-imidazol-5-yl}-1,11-dihydroisochromeno[4',3&#x2032;:6,7]naphtho[1,2-d]imidazol-2-yl)-5-methylpyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl}carbamate (Compound I) were prepared and characterized in the solid state:  Also provided are processes of manufacture and methods of using these crystalline forms.

Solid forms of an antiviral compound

Polymorphs of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one, compositions thereof, methods for their preparation, and methods for their use are disclosed.

Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one

Crystalline solid forms of methyl {(2S)-1-[(2S,5S)-2-(9-{2-[(2S,4S)-1-{(2R)-2-[(methoxycarbonyl)amino]-2-phenylacetyl}-4-(methoxymethyl)pyrrolidin-2-yl]-1H-imidazol-5-yl}-1,11-dihydroisochromeno[4',3&#x2032;:6,7]naphtho[1,2-d]imidazol-2-yl)-5-methylpyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl}carbamate (Compound I) were prepared and characterized in the solid state: Also provided are processes of manufacture and methods of using these crystalline forms.

Polymorphs of a hydrochloride salt of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one, compositions thereof, methods for their preparation, and methods for their use are disclosed. Solvent forms of a hydrochloride salt of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one, compositions thereof, methods for their preparation, and methods for their use are also disclosed.

Polymorphic forms of a hydrochloride salt of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one

The present invention provides crystalline forms, solvates and hydrates of 4-amino-2-butoxy-8-(3-(pyrrolidin-1-ylmethyl)benzyl)-7,8-dihydropteridin-6(5H)-one, and methods of making.

Solid forms of a toll-like receptor modulator

The present invention relates to co-crystals, salts and crystalline forms of tenofovir alafenamide and methods for preparation, use and isolation of such compounds.

Co-crystals, salts and solid forms of tenofovir alafenamide

Growing community of inventors

Foster City, CA, United States of America

Fang Wang